IDO2 and neoplasm: Lu et al. (2016) encapsulated a small-molecule immunotherapy agent, which inhibits indoleamine 2,3-dioxygenase (IDO), into a chlorin-based nanoscale metal-organic framework and the post-PDT treatment reported successful systematic anti-tumor immunity in CRC models [49].